Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadrivalent influenza vaccine (Jiangsu GDK Biotechnology)
- Development stage
- Unknown
- Lead developer
- Jiangsu gdk Biotechnology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This quadrivalent inactivated influenza split-virion vaccine (IIV4) is developed and manufactured by Jiangsu GDK Biotechnology (also known as Jiangsu Jindike). It is designed to provide broad protection against seasonal influenza by including antigens from four distinct virus strains: two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). Each 0.5 mL dose contains 15 μg of hemagglutinin per strain, totaling 60 μg. The vaccine works by inducing a protective immune response, specifically the production of neutralizing antibodies against the viral hemagglutinin. It is administered via intramuscular injection and is approved in China for use in adults and children aged 3 years and older.
- Brand names
- Jindike
- Other names
- Quadrivalent inactivated influenza split-virion vaccineIIV4 (Jiangsu GDK)Jiangsu Jindike quadrivalent influenza vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on quadrivalent influenza vaccine (Jiangsu GDK Biotechnology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadrivalent influenza vaccine (Jiangsu GDK Biotechnology).